Dietary cholesterol in alcohol-associated liver disease-Immunometabolism-CSCIED科技核心评价数据库-手机版

Dietary cholesterol in alcohol-associated liver disease

Dietary cholesterol in alcohol-associated liver disease

ES评分 0 浏览量：962 下载量：0

DOI	10.1097/IN9.0000000000000026
刊名	Immunometabolism IJ
年，卷(期)	2023, 5(2)
作者	Jia, Lin,
作者单位	[Jia, Lin] Univ Texas Dallas, Dept Biol Sci, Richardson, TX 75080 USA
摘要	There is an increasing prevalence of alcohol-associated liver disease (ALD) worldwide. In addition to excessive alcohol consumption, other nutritional factors have been shown to affect the initiation and progression of ALD. The emerging role of cholesterol in exacerbating ALD has been reported recently and the underlying mechanisms are discussed. In addition, the interplay between dietary cholesterol and alcohol on cholesterol metabolism is reviewed. Furthermore, we highlight the therapeutic potential of cholesterol-lowering drugs in managing the onset and severity of ALD. Finally, we suggest the future mechanistic investigation of the effect of cholesterol on insulin resistance and intestinal inflammation in the exacerbation of alcohol-induced cellular and systemic dysfunction.
Abstract	There is an increasing prevalence of alcohol-associated liver disease (ALD) worldwide. In addition to excessive alcohol consumption, other nutritional factors have been shown to affect the initiation and progression of ALD. The emerging role of cholesterol in exacerbating ALD has been reported recently and the underlying mechanisms are discussed. In addition, the interplay between dietary cholesterol and alcohol on cholesterol metabolism is reviewed. Furthermore, we highlight the therapeutic potential of cholesterol-lowering drugs in managing the onset and severity of ALD. Finally, we suggest the future mechanistic investigation of the effect of cholesterol on insulin resistance and intestinal inflammation in the exacerbation of alcohol-induced cellular and systemic dysfunction.
关键词	alcohol; alcohol-associated liver disease; cholesterol; cholesterol-lowering pharmacotherapies
KeyWord	alcohol; alcohol-associated liver disease; cholesterol; cholesterol-lowering pharmacotherapies
基金项目
页码	1-6

参考文献
相关文献

[1]. Julien J, Ayer T, Bethea ED, et al. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. Lancet Public Health. 2020;5(6):e316–23.

[2]. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.

[3]. Barve S, Chen SY, Kirpich I, et al. Development, prevention, and treatment of alcohol-induced organ injury: the role of nutrition. Alcohol Res. 2017;38(2):289–302.

[4]. Tanisawa K, Ito T, Kawakami R, et al. Association between alcohol dietary pattern and prevalence of dyslipidaemia: WASEDA’S Health Study. Br J Nutr. 2022;127(11):1712–22.

[5]. Horn CL, Morales AL, Savard C, et al. Role of cholesterol-associated steatohepatitis in the development of NASH. Hepatol Commun. 2022;6(1):12–35.

[6]. Yvan-Charvet L, Bonacina F, Guinamard RR, et al. Immunometabolic function of cholesterol in cardiovascular disease and beyond. Cardiovasc Res. 2019;115(9):1393–407.

[7]. Li H, Yu XH, Ou X, et al. Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. Prog Lipid Res. 2021;83:101109.

[8]. Cederbaum AI. Role of CYP2E1 in ethanol-induced oxidant stress, fatty liver and hepatotoxicity. Dig Dis. 2010;28(6):802–11.

[9]. Frenzer A, Butler WJ, Norton ID, et al. Polymorphism in alcohol-metabolizing enzymes, glutathione S-transferases and apolipoprotein E and susceptibility to alcohol-induced cirrhosis and chronic pancreatitis. J Gastroenterol Hepatol. 2002;17(2):177–82.

[10]. Suzuki Y, Ando F, Ohsawa I, et al. Association of alcohol dehydrogenase 2*1 allele with liver damage and insulin concentration in the Japanese. J Hum Genet. 2006;51(1):31–7.

[11]. Monzoni A, Masutti F, Saccoccio G, et al. Genetic determinants of ethanol-induced liver damage. Mol Med. 2001;7(4):255–62.

[12]. Tsutsumi M, Takada A, Wang JS. Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease. Gastroenterology. 1994;107(5):1430–5.

[13]. Tanaka F, Shiratori Y, Yokosuka O, et al. Polymorphism of alcohol-metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. Alcohol Clin Exp Res. 1997;21(4):596–601.

[14]. Munaka M, Kohshi K, Kawamoto T, et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2003;129(6):355–60.

[15]. Abe H, Aida Y, Seki N, et al. Aldehyde dehydrogenase 2 polymorphism for development to hepatocellular carcinoma in East Asian alcoholic liver cirrhosis. J Gastroenterol Hepatol. 2015;30(9):1376–83.

[16]. Seo W, Gao Y, He Y, et al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles. J Hepatol. 2019;71(5):1000–11.

[17]. Morgan K, French SW, Morgan TR. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology. 2002;36(1):122–34.

[18]. Butura A, Nilsson K, Morgan K, et al. The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol. 2009;50(3):572–83.

[19]. Gouillon Z, Lucas D, Li J, et al. Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med. 2000;224(4):302–8.

[20]. Albano E, Clot P, Morimoto M, et al. Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Hepatology. 1996;23(1):155–63.

[21]. Morimoto M, Hagbjork AL, Wan YJ, et al. Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology. 1995;21(6):1610–7.

[22]. Diesinger T, Buko V, Lautwein A, et al. Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis. PLoS One. 2020;15(7):e0235990.

[23]. Nanji AA, Zhao S, Sadrzadeh SM, et al. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats. Alcohol Clin Exp Res. 1994;18(5):1280–5.

[24]. Takahashi H, Johansson I, French SW, et al. Effects of dietary fat composition on activities of the microsomal ethanol oxidizing system and ethanol-inducible cytochrome P450 (CYP2E1) in the liver of rats chronically fed ethanol. Pharmacol Toxicol. 1992;70(5 Pt 1):347–51.

[25]. Lopez-Islas A, Chagoya-Hazas V, Perez-Aguilar B, et al. Cholesterol enhances the toxic effect of ethanol and acetaldehyde in primary mouse hepatocytes. Oxid Med Cell Longev. 2016;2016:9209825.

[26]. Dey A, Cederbaum AI. Alcohol and oxidative liver injury. Hepatology. 2006;43(2 Suppl 1):S63–74.

[27]. Krishnasamy Y, Ramshesh VK, Gooz M, et al. Ethanol and high cholesterol diet causes severe steatohepatitis and early liver fibrosis in mice. PLoS One. 2016;11(9):e0163342.

[28]. Li B, Lei S-S, Su J, et al. Alcohol induces more severe fatty liver disease by influencing cholesterol metabolism. Evid Based Complement Alternat Med. 2019;2019:7095684.

[29]. Zhong W, Zhao Y, Tang Y, et al. Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am J Pathol. 2012;180(3):998–1007.

[30]. Clugston RD, Yuen JJ, Hu Y, et al. CD36-deficient mice are resistant to alcohol- and high-carbohydrate-induced hepatic steatosis. J Lipid Res. 2014;55(2):239–46.

[31]. Sugimoto T, Yamashita S, Ishigami M, et al. Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol. 2002;36(2):157–62.

[32]. Kharbanda KK, Todero SL, Ward BW, et al. Betaine administration corrects ethanol-induced defective VLDL secretion. Mol Cell Biochem. 2009;327(1-2):75–8.

[33]. Wang HJ, Gao B, Zakhari S, et al. Inflammation in alcoholic liver disease. Annu Rev Nutr. 2012;32:343–68.

[34]. Gao B, Ahmad MF, Nagy LE, et al. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol. 2019;70(2):249–59.

[35]. Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab. 2016;27(2):84–95.

[36]. Galligan JJ, Smathers RL, Shearn CT, et al. Oxidative stress and the ER stress response in a murine model for early-stage alcoholic liver disease. J Toxicol. 2012;2012:207594.

[37]. Galicia-Moreno M, Rosique-Oramas D, Medina-Avila Z, et al. Behavior of oxidative stress markers in alcoholic liver cirrhosis patients. Oxid Med Cell Longev. 2016;2016:9370565.

[38]. Cho YE, Mezey E, Hardwick JP, et al. Increased ethanol-inducible cytochrome P450-2E1 and cytochrome P450 isoforms in exosomes of alcohol-exposed rodents and patients with alcoholism through oxidative and endoplasmic reticulum stress. Hepatol Commun. 2017;1(7):675–90.

[39]. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006;4(3):185–98.

[40]. DeCarli LM, Lieber CS. Fatty liver in the rat after prolonged intake of ethanol with a nutritionally adequate new liquid diet. J Nutr. 1967;91(3):331–6.

[41]. Bertola A, Mathews S, Ki SH, et al. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc. 2013;8(3):627–37.

[42]. Tomita K, Teratani T, Suzuki T, et al. Acyl-CoA: cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells. J Hepatol. 2014;61(1):98–106.

[43]. Lefevre AF, DeCarli LM, Lieber CS. Effect of ethanol on cholesterol and bile acid metabolism. J Lipid Res. 1972;13(1):48–55.

[44]. Middleton WR, Carter EA, Drummey GD, et al. Effect of oral ethanol administration on intestinal cholesterogenesis in the rat. Gastroenterology. 1971;60(5):880–7.

[45]. Wang Z, Yao T, Song Z. Chronic alcohol consumption disrupted cholesterol homeostasis in rats: down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liver. Alcohol Clin Exp Res. 2010;34(3):471–8.

[46]. Brinton EA. Effects of ethanol intake on lipoproteins. Curr Atheroscler Rep. 2012;14(2):108–14.

[47]. Ito DT, Molina HM, Andriolo A, et al. The combination of atorvastatin and ethanol is not more hepatotoxic to rats than the administration of each drug alone. Braz J Med Biol Res. 2007;40(3):343–8.

[48]. Pirillo A, Catapano AL, Norata GD. Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases. Curr Med Chem. 2016;23(10):983–99.

[49]. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007;581(29):5664–70.

[50]. Ushio M, Nishio Y, Sekine O, et al. Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet. Am J Physiol Endocrinol Metab. 2013;305(2):E293–304.

[51]. Loomba R, Sirlin CB, Ang B, et al.; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61(4):1239–50.

[52]. Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol. 2022;14(1):119–39.

[53]. Robinson JG, Farnier M, Krempf M, et al.; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.

[54]. Sabatine MS, Giugliano RP, Wiviott SD, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9.

[55]. Lohoff FW, Sorcher JL, Rosen AD, et al. Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder. Mol Psychiatry. 2018;23(9):1900–10.

[56]. Lee JS, Mukhopadhyay P, Matyas C, et al. PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease. Sci Rep. 2019;9(1):17167.

[57]. Bell DS. Alcohol and the NIDDM patient. Diabetes Care. 1996;19(5):509–13.

[58]. Bukiya A, Dopico AM, Leffler CW, et al. Dietary cholesterol protects against alcohol-induced cerebral artery constriction. Alcohol Clin Exp Res. 2014;38(5):1216–26.

[59]. Piano MR, Mazzuco A, Kang M, et al. Cardiovascular consequences of binge drinking: an integrative review with implications for advocacy, policy, and research. Alcohol Clin Exp Res. 2017;41(3):487–96.

[60]. Simakova MN, Bisen S, Dopico AM, et al. Statin therapy exacerbates alcohol-induced constriction of cerebral arteries via modulation of ethanol-induced BK channel inhibition in vascular smooth muscle. Biochem Pharmacol. 2017;145:81–93.

[61]. Uchiyama S, Nakaya N, Mizuno K, et al.; MEGA Study Group. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. J Neurol Sci. 2009;284(1-2):72–6.

[62]. Bukiya AN, Blank PS, Rosenhouse-Dantsker A. Cholesterol intake and statin use regulate neuronal G protein-gated inwardly rectifying potassium channels. J Lipid Res. 2019;60(1):19–29.

[63]. Hernandez-Rubio A, Sanvisens A, Bolao F, et al. Prevalence and associations of metabolic syndrome in patients with alcohol use disorder. Sci Rep. 2022;12(1):2625.

[64]. Carr RM, Dhir R, Yin X, et al. Temporal effects of ethanol consumption on energy homeostasis, hepatic steatosis, and insulin sensitivity in mice. Alcohol Clin Exp Res. 2013;37(7):1091–9.

[65]. Bosner MS, Lange LG, Stenson WF, et al. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res. 1999;40(2):302–8.

[66]. Basciano H, Miller AE, Naples M, et al. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab. 2009;297(2):E462–73.

[67]. Naples M, Baker C, Lino M, et al. Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2012;302(9):G1043–52.

[68]. Sugizaki T, Watanabe M, Horai Y, et al. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice. Endocrinology. 2014;155(8):2810–9.

[69]. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–61.

[70]. Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094–8.

[71]. Progatzky F, Sangha NJ, Yoshida N, et al. Dietary cholesterol directly induces acute inflammasome-dependent intestinal inflammation. Nat Commun. 2014;5:5864.

[72]. Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. J Hepatol. 2019;70(2):260–72.

引用本文

Jia, Lin. Dietary cholesterol in alcohol-associated liver disease [J]. Immunometabolism. 2023; 5; (2). 1 - 6.

文献评论

相关学者

相关机构